C07H19/04

Compositions and methods for enhancing bioenergetic status in female germ cells

Compositions and methods comprising bioenergetic agents for restoring the quality of aged oocytes, enhancing oogonial stem cells or improving derivatives thereof (e.g., cytoplasm or isolated mitochondria) for use in fertility-enhancing procedures, are described.

Tunable fluorescence using cleavable linkers

The invention relates to cleavable chemistry in general, and in particular, to tunable fluorescence using cleavable linkers present in fluorochrome-quencher conjugates.

Synthetic route to 2′-deoxy-2′,2′-difluorotetrahydrouridines

The present invention relates to methods and intermediates for synthesizing 2′-deoxy-2′,2′-difluorotetrahydrouridine compounds.

Synthetic route to 2′-deoxy-2′,2′-difluorotetrahydrouridines

The present invention relates to methods and intermediates for synthesizing 2′-deoxy-2′,2′-difluorotetrahydrouridine compounds.

Bridged-cyclo-ProTides as prodrugs of therapeutic nucleosides and nucleotides
09828409 · 2017-11-28 ·

Provided herein are bridged cyclic phosphates and phosphoramidates (bc-ProTides) of nucleosides, which is a compound, its stereoisomers, isotope-enriched analogs, pharmaceutically acceptable salts, hydrates, solvates, or crystalline or polymorphic forms thereof, with the following structure: ##STR00001##
These compounds can be used for the treatment of viral infections and/or neoplastic diseases in mammals. By optimizing combinations of Y.sub.2, Y.sub.3, R.sup.0, and M, the cleavability of these compounds as prodrugs can be attuned for different tissue targeting with various functional combinations. Also disclosed are processes and methods for preparation of these compounds.

Bridged-cyclo-ProTides as prodrugs of therapeutic nucleosides and nucleotides
09828409 · 2017-11-28 ·

Provided herein are bridged cyclic phosphates and phosphoramidates (bc-ProTides) of nucleosides, which is a compound, its stereoisomers, isotope-enriched analogs, pharmaceutically acceptable salts, hydrates, solvates, or crystalline or polymorphic forms thereof, with the following structure: ##STR00001##
These compounds can be used for the treatment of viral infections and/or neoplastic diseases in mammals. By optimizing combinations of Y.sub.2, Y.sub.3, R.sup.0, and M, the cleavability of these compounds as prodrugs can be attuned for different tissue targeting with various functional combinations. Also disclosed are processes and methods for preparation of these compounds.

Modulators of 5′-nucleotidase, ecto and the use thereof

Compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

Modulators of 5′-nucleotidase, ecto and the use thereof

Compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

Reagents useful for synthesizing rhodamine-labeled oligonucleotides

The present disclosure provides reagents that can be used to label synthetic oligonucleotides with rhodamine dyes or dye networks that contain rhodamine dyes.

Reagents useful for synthesizing rhodamine-labeled oligonucleotides

The present disclosure provides reagents that can be used to label synthetic oligonucleotides with rhodamine dyes or dye networks that contain rhodamine dyes.